A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis
A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis
The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.
Inclusion Criteria:
Exclusion Criteria:
global-roche-genentech-trials@gene.com888-662-6728 (U.S. Only)
Naples, Campania 80138, Italy
Roma, Emilia-Romagna 00133, Italy
Milan, Lombardy 20162, Italy
Christchurch Central City, South Island 8011, New Zealand
Poznan, Greater Poland Voivodeship 61-853, Poland
Rzeszw, Podkarpackie Voivodeship 35-323, Poland
?ory, 44-240, Poland
?ód?, 90-368, Poland
Gda?sk, 80-803, Poland
Krakow, 31-503, Poland
Wroc?aw, 54-239, Poland
Zabrze, 41-800, Poland
Lisbon, 1169-050, Portugal
Santa Maria da Feira, 4520-211, Portugal
Santiago de Compostela, LA Coruna 15706, Spain
Istanbul, 34785, Turkey (Türkiye)